210 related articles for article (PubMed ID: 23863359)
1. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.
Walters CL; Arend RC; Armstrong DK; Naumann RW; Alvarez RD
Gynecol Oncol; 2013 Nov; 131(2):493-8. PubMed ID: 23863359
[TBL] [Abstract][Full Text] [Related]
2. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
4. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.
Vergote IB; Marth C; Coleman RL
Cancer Metastasis Rev; 2015 Mar; 34(1):41-52. PubMed ID: 25564455
[TBL] [Abstract][Full Text] [Related]
5. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
Kamen BA; Smith AK
Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
[TBL] [Abstract][Full Text] [Related]
6. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
7. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
8. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
10. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
[TBL] [Abstract][Full Text] [Related]
11. Farletuzumab in lung cancer.
Thomas A; Maltzman J; Hassan R
Lung Cancer; 2013 Apr; 80(1):15-8. PubMed ID: 23357463
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
13. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
Ledermann JA; Canevari S; Thigpen T
Ann Oncol; 2015 Oct; 26(10):2034-43. PubMed ID: 26063635
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
15. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
[TBL] [Abstract][Full Text] [Related]
16. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
18. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.
Ziebarth AJ; Landen CN; Alvarez RD
Clin Obstet Gynecol; 2012 Mar; 55(1):156-72. PubMed ID: 22343235
[TBL] [Abstract][Full Text] [Related]
19. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
